Results 161 to 170 of about 34,183 (229)

HIV drug resistance to integrase inhibitors in low- and middle-income countries. [PDF]

Nat Med
Fokam J, Inzaule S, Colizzi V, Perno CF, Kaseya J, Ndembi N.   +5 more
europepmc   +1 more source

Safety and Efficacy of Pharmacotherapy Containing the Second-Generation Integrase Inhibitors and Chemotherapy Drugs in AIDS-Related Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Analysis. [PDF]

Oncol Res Treat
Yang J, Cheng X, Wei G, Chen T, Zhao Y, Zhao Y.   +5 more
europepmc   +1 more source

Optimizing the Multimerization Properties of Quinoline-Based Allosteric HIV-1 Integrase Inhibitors. [PDF]

Viruses
Sun J, Kessl JJ.
europepmc   +1 more source

Risk of viral failure after simplification therapy without using integrase inhibitors compared with maintenance of triple antiretroviral therapy: A systematic review and meta-analysis. [PDF]

Braz J Infect Dis
Helfer MS, Sprinz E.
europepmc   +1 more source

Novel machine learning approach toward classification model of HIV-1 integrase inhibitors. [PDF]

RSC Adv
Phan TL, Trinh TC, To VT, Pham TA, Van Nguyen PC, Phan TM, Truong TN.   +6 more
europepmc   +1 more source

A systematic review and meta-analysis of maternal weight changes and pregnancy outcomes associated with integrase inhibitors and tenofovir alafenamide in pregnant women with HIV. [PDF]

Am J Obstet Gynecol MFM
Eke AC, Ramaiyer M, Eleje GU, Ezebialu IU, Aliyu MH.   +4 more
europepmc   +1 more source

Detection of viruses in clinical samples by use of metagenomic sequencing and targeted sequence capture [PDF]

, 2018
Buller, Richard, Cannella, Maria T, Herter, Brandi, Storch, Gregory A, Wylie, Kristine M, Wylie, Todd N   +5 more
core   +1 more source

Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors. [PDF]

Front Immunol
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Muñoz-Muela E, Álvarez-Ríos AI, Lozano C, Llaves-Flores S, Espinosa N, Roca-Oporto C, Herrero M, Sotomayor C, Gutierrez-Valencia A, Lopez-Cortes LF.   +12 more
europepmc   +1 more source

Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors. [PDF]

BMJ Open
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A, PRESTIGIO Study Group.   +19 more
europepmc   +1 more source